OvaScience (NASDAQ: OVAS) is one of 184 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare OvaScience to similar businesses based on the strength of its valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.
Risk & Volatility
OvaScience has a beta of 3.73, indicating that its stock price is 273% more volatile than the S&P 500. Comparatively, OvaScience’s rivals have a beta of 1.56, indicating that their average stock price is 56% more volatile than the S&P 500.
This table compares OvaScience and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares OvaScience and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|OvaScience Competitors||$217.36 million||-$39.57 million||-62.73|
OvaScience’s rivals have higher revenue and earnings than OvaScience. OvaScience is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
55.1% of OvaScience shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 9.5% of OvaScience shares are owned by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a summary of current ratings and target prices for OvaScience and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OvaScience currently has a consensus target price of $8.00, suggesting a potential upside of 440.54%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.06%. Given OvaScience’s higher probable upside, research analysts clearly believe OvaScience is more favorable than its rivals.
OvaScience rivals beat OvaScience on 8 of the 13 factors compared.
OvaScience Company Profile
OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.